BPC-157 Tissue Repair Peptide — A Complete Scientific Guide
Derived from human gastric mucosa, BPC-157 (Body Protection Compound-157) is one of the best-documented research peptides preclinically for its effects on tendon healing, gastric protection, neuroprotection and modulation of the NO system.
What is the BPC-157?
Le BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) with the sequence GEPPPGKPADDAGLV, partially derived from the sequence of the human body fixative protein (human BPC) present in gastric juice.
Synthesized and studied since the 1990s by Professor Predrag Sikiric's team in Zagreb, BPC-157 is one of the most published research peptides in scientific databases with over 200 preclinical studies indexed in PubMed.
Documented mechanisms of action
Modulation of the NO (nitric oxide) system
The main mechanism attributed to BPC-157 is the modulation of the nitric oxide (NO) systemNitric oxide (NO) is a vasodilator and crucial second messenger involved in angiogenesis, wound healing, and the inflammatory response.
- Endothelial NOS (eNOS) activation in vascular cells
- Protection of endothelial cells against oxidative damage
- Promoting local angiogenesis (formation of new blood vessels) at injury sites
- Documented interaction with the NO-sGC-cGMP pathway in smooth muscle
Stimulation of tendon and muscle cell growth
In vitro studies show that BPC-157 stimulates the expression of growth factor receptors (EGF-R, VEGFR-2) in tendon fibroblasts, accelerating their proliferation and migration to the site of injury.
Modulation of dopaminergic receptors
Studies in rats show that BPC-157 modulates dopaminergic receptors D1 and D2, which would explain some of the effects observed on behavior, motor skills, and neurological recovery.
Effects on tissue healing (preclinical studies)
Tendons and ligaments
This is probably the best-documented area of BPC-157. Studies in rats with surgical sectioning of the Achilles tendon show:
- Acceleration of collagen reorganization and local neovascularization
- Improvement in tendon tensile strength during healing at 1, 2 and 4 weeks
- Effects observed via systemic administration et by local peritendinous injection
Skeletal muscle
Rat models of muscle injury by crush injury show a reduction in muscle strength recovery time and a reduction in fibrosis at the injury site with BPC-157 vs control.
Skin and skin healing
Studies on excised wounds in rats show accelerated wound closure, improved scar quality (collagen fiber orientation, vascularization) and a reduction in local inflammation.
Gastric and intestinal protection
BPC-157 owes its original name to its gastric mucosal protective properties. These effects are among the most robustly documented:
- Prevention of gastric ulcers induced by aspirin, ethanol, or pyloric ligation in mouse models
- Protection against NSAIDs: reduction of gastric and intestinal lesions induced by indomethacin, diclofenac
- Accelerated healing pre-existing gastric and duodenal ulcers
- Intestinal anti-inflammatory effects in colitis models (TNBS, DSS)
These properties are mechanistically consistent with the origin of the peptide (human gastric mucosa) and with its modulation of the NO system and prostaglandins.
Neuroprotection and the central nervous system
A more recent and promising area of research concerns the effects of BPC-157 on the nervous system:
- Reduction of neurological deficits in rat models of traumatic brain injury
- Dopaminergic protection in induced Parkinson's disease (6-OHDA) models
- Accelerated motor recovery after partial spinal cord transection
- Modulation of the hypothalamic-pituitary axis in certain stress models
These neuroprotective data remain primarily preclinical and require validation in more complex models before any extrapolation.
Stability and technical specifications
| Property | Value |
|---|---|
| Sequence | GEPPPGKPADDAGLV |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular mass | 1,419.5 Da |
| Solubility | Water (good intrinsic solubility) |
| Optimal shape | Freeze-dried (white powder) |
| Stability in solution | Stable — resistant to gastric juices (characteristic) |
| Freeze-dried preservation | 12-24 months at 2-8°C |
| Recommended solvent | Bacteriostatic Water USP |
Unlike many peptides, BPC-157 exhibits remarkable resistance to degradation by gastric enzymes, consistent with its origin in the gastric mucosa. This property is scientifically interesting for comparative studies of oral versus injected administration.
State of clinical research
Despite the very large number of preclinical studies (rodents, rabbits, guinea pigs), human clinical data on BPC-157 remain very limited to date:
- No large-scale phase 2 or 3 clinical trials have been published.
- Some case reports and small series in sports medicine
- Exploratory trials have been initiated, but formal results are lacking.
The BPC-157 therefore remains a preclinical research compound, with a well-documented mechanistic rationale but still insufficient clinical validation for any therapeutic conclusion.
Applications in laboratory research
In a scientific research context, BPC-157 is typically studied for:
- Models of tissue healing (tendon, muscle, skin)
- Research on gastrointestinal protection and repair
- Investigation of the mechanisms of local angiogenesis
- Studies of the NO system and endothelial signaling
- Models of neuroprotection and neurological recovery
- Research on NSAID-induced lesions
BPC-157 certified HPLC 99%+ available
MyPeptide offers research-grade BPC-157 in 5 mg, 10 mg, and 20 mg strengths, with a Janoshik certificate of analysis. Shipping from the European Union within 48-72 hours.